{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:08:47Z","timestamp":1787022527588,"version":"build-2736575974"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0352_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In serum immunofixation electrophoresis, therapeutic monoclonal antibodies (tmAbs) can be misinterpreted as paraproteins. Strategies to circumvent these interferences include the use of anti-tmAb antibodies, which led to the development of the Hydrashift assay. However, this assay is exclusively available for the Sebia platform and limited to specific tmAbs, such as daratumumab (DmAb) and isatuximab (ImAb). Furthermore, we observed some cases in which complete shifting of tmAbs by the Hydrashift Assay was questionable. This study aimed to explore isoelectric focusing (IEF) as an alternative, widely applicable method for clinical laboratories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0352_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>First, the neutralization capacity of the DmAb and ImAb Hydrashift assay was assessed by testing undiluted tmAb samples. Second, DmAb and ImAb were spiked into paraprotein-containing samples in clinically relevant concentrations and analyzed by the Hydrashift assay and IEF. Presence of unshifted tmAb and identification of tmAb and paraproteins were examined in these samples and routinely collected patient samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0352_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Hydrashift assay reliably shifted up to 0.5\u202fg\/L DmAb and up to 1.5\u202fg\/L ImAb. IEF was found to be equally effective as the Hydrashift assay in identifying antibody interferences and detecting paraproteins. Additionally, IEF successfully identified two pseudo-monoclonal gammopathies as oligoclonal and detected other therapeutic antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0352_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Insufficient neutralization capacity of the Hydrashift Assay was not observed within the clinically relevant range of investigated tmAb concentrations. IEF offers a simple and flexible alternative to the Hydrashift assay for distinguishing tmAbs from paraproteins. Its advantages include broader applicability to various tmAbs and independency from specific commercial platforms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0352","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:57:39Z","timestamp":1747828659000},"page":"1766-1772","source":"Crossref","is-referenced-by-count":3,"title":["Beyond the Hydrashift assay: the utility of isoelectric focusing for therapeutic antibody and paraprotein detection"],"prefix":"10.1515","volume":"63","author":[{"given":"Rieke","family":"Reiter","sequence":"first","affiliation":[{"name":"Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics , Philipps-University Marburg , Marburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology, Oncology and Immunology , University Hospital Marburg , Marburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Andreas","family":"Nockher","sequence":"additional","affiliation":[{"name":"Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics , Philipps-University Marburg , Marburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"2026051215061098204_j_cclm-2025-0352_ref_001","doi-asserted-by":"crossref","unstructured":"Kyle, RA, Gertz, MA, Witzig, TE, Lust, JA, Lacy, MQ, Dispenzieri, A, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21\u20133. https:\/\/doi.org\/10.4065\/78.1.21.","DOI":"10.4065\/78.1.21"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_002","doi-asserted-by":"crossref","unstructured":"Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_003","doi-asserted-by":"crossref","unstructured":"Caillon, H, Irimia, A, Simon, JS, Axel, A, Sasser, K, Scullion, MJ, et al.. Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry-developed Dira test: Hydrashift 2\/4 Daratumumab. Blood 2016;128:2063. https:\/\/doi.org\/10.1182\/blood.v128.22.2063.2063.","DOI":"10.1182\/blood.V128.22.2063.2063"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_004","doi-asserted-by":"crossref","unstructured":"McCudden, C, Axel, A, Slaets, D, Frans, S, Bald, J, Schecter, J, et al.. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA). J Clin Oncol 2015;A8590.","DOI":"10.1200\/jco.2015.33.15_suppl.8590"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_005","doi-asserted-by":"crossref","unstructured":"Kirchhoff, DC, Murata, K, Thoren, KL. Use of a daratumumab-Specific immunofixation assay to assess possible immunotherapy interference at a major cancer center: our experience and recommendations. J Appl Lab Med 2021;6:1476\u201383. https:\/\/doi.org\/10.1093\/jalm\/jfab055.","DOI":"10.1093\/jalm\/jfab055"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_006","doi-asserted-by":"crossref","unstructured":"Lee, HW, Kim, SM, Park, HD. Evaluating the Hydrashift 2\/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma. Clin Chem Lab Med 2024;62:2223\u201332. https:\/\/doi.org\/10.1515\/cclm-2024-0416.","DOI":"10.1515\/cclm-2024-0416"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_007","unstructured":"Cornell, FN, McLachlan, R. Isoelectric focusing in the investigation of gammopathies. Sydney: Australian Association of Clinical Biochemists; 1985:31\u20137 pp."},{"key":"2026051215061098204_j_cclm-2025-0352_ref_008","doi-asserted-by":"crossref","unstructured":"Kim, K, Phelps, MA. Clinical pharmacokinetics and pharmacodynamics of daratumumab. Clin Pharmacokinet 2023;62:789\u2013806. https:\/\/doi.org\/10.1007\/s40262-023-01240-8.","DOI":"10.1007\/s40262-023-01240-8"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_009","doi-asserted-by":"crossref","unstructured":"Xu, XS, Dimopoulos, MA, Sonneveld, P, Ho, PJ, Belch, A, Leiba, M, et al.. Pharmacokinetics and exposure\u2013response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther 2018;35:1859\u201372. https:\/\/doi.org\/10.1007\/s12325-018-0815-9.","DOI":"10.1007\/s12325-018-0815-9"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_010","unstructured":"European Medicines Agency. Darzalex \u2013 Daratumumab. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/darzalex [Accessed March 2024]."},{"key":"2026051215061098204_j_cclm-2025-0352_ref_011","doi-asserted-by":"crossref","unstructured":"Martin, T, Strickland, S, Glenn, M, Charpentier, E, Guillemin, H, Hsu, K, et al.. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J 2019;9:41. https:\/\/doi.org\/10.1038\/s41408-019-0198-4.","DOI":"10.1038\/s41408-019-0198-4"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_012","doi-asserted-by":"crossref","unstructured":"Sunami, K, Suzuki, K, Ri, M, Matsumoto, M, Shimazaki, C, Asaoku, H, et al.. Isatuximab monotherapy in relapsed\/refractory multiple myeloma: a Japanese, multicenter, phase 1\/2, safety and efficacy study. Cancer Sci 2020;111:4526\u201339. https:\/\/doi.org\/10.1111\/cas.14657.","DOI":"10.1111\/cas.14657"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_013","doi-asserted-by":"crossref","unstructured":"Simonelli, M, Garralda, E, Eskens, F, Gil-Martin, M, Yen, CJ, Obermannova, R, et al.. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I\/II, open-label, multicenter study. ESMO Open 2022;7:100562. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100562.","DOI":"10.1016\/j.esmoop.2022.100562"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_014","doi-asserted-by":"crossref","unstructured":"Mikhael, J, Richter, J, Vij, R, Cole, C, Zonder, J, Kaufman, JL, et al.. A dose-finding phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed\/refractory multiple myeloma. Leukemia 2020;34:3298\u2013309. https:\/\/doi.org\/10.1038\/s41375-020-0857-2.","DOI":"10.1038\/s41375-020-0857-2"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_015","doi-asserted-by":"crossref","unstructured":"Thoren, KL, Pianko, MJ, Maakaroun, Y, Landgren, CO, Ramanathan, LV. Distingushing drug from disease by use of the Hydrashift 2\/4 Daratumumab assay. J App Lab Med 2019;3:857\u201363. https:\/\/doi.org\/10.1373\/jalm.2018.026476.","DOI":"10.1373\/jalm.2018.026476"},{"key":"2026051215061098204_j_cclm-2025-0352_ref_016","unstructured":"HYDRASHIFT 2\/4 daratumumab (20 tests) Ref. 4639, package insert, version 22\/5. Sebia, Lisses, France."},{"key":"2026051215061098204_j_cclm-2025-0352_ref_017","doi-asserted-by":"crossref","unstructured":"Wheeler, RD, Costa, MV, Crichlow, A, Willis, F, Reyal, Y, Linstead, SE, et al.. Case report: interference from isatuximab on serum protein electrophoresis prevented demonstration of complete remission in a myeloma patient. Ann Clin Biochem 2022;59:144\u20138. https:\/\/doi.org\/10.1177\/00045632211062080.","DOI":"10.1177\/00045632211062080"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0352\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:07:00Z","timestamp":1778598420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0352\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,8,26]]}},"alternative-id":["10.1515\/cclm-2025-0352"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0352","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}